Investigating the Heterogeneity and Trajectory of the Neurocognitive Disorder in Patients with Parkinson'S Disease( III )

高齡社會下，巴金森氏病患者人口漸增，在動作症狀獲得良好治療下，患者常合併神經認知疾患，對病程影響甚鉅。本研究結合臨床神經心理和分子生物科技來釐清台灣巴金森氏病患者神經認知疾患之致病機制與發展軌跡，並透過發展修訂工具提升診斷效力，期望未來在早期偵測與介入策略上提出建議，進而讓國家有效運用投入之社會與經濟資源，降低醫療過程中國家社會之經濟成本支出，緩解人口結構改變帶來之衝擊。

Background: Taiwan became an aging society in 2018 and is projected to reach the status of a super-aged society by 2026. As a result, the prevalence of neurodegenerative diseases is expected to rise. Parkinson’s disease (PD) neurocognitive disorder (NCD) significantly affects the quality of life for both patients and their families, with mild NCD representing a critical prodromal stage for disease progression. Current diagnostic criteria remain inadequate, particularly regarding social function assessment and cross-population validity. This study aims to combine clinical and genetic assessments to explore cognitive and social function issues in PD and to develop a diagnostic tool tailored to the Taiwanese population.

Method: We conducted a three-year prospective, nested casecontrol study, utilizing clinical neuropsychological assessments and genomic analyses to investigate heterogeneity and changes in neurocognitive function among PD patients. Additionally, we applied psychometric methods to develop a diagnostic tool.